<DOC>
	<DOCNO>NCT02284191</DOCNO>
	<brief_summary>This study aim investigate effect early CTCA patient suspect confirmed Acute Coronary Syndrome ( ACS ) present Emergency Department ( ED ) Medical Assessment Unit ( MAU ) , upon intervention , event rate health care cost pragmatic clinical trial economic evaluation 1 year trial intervention . The primary objective investigate effect intervention proportion patient all-cause death recurrent non-fatal type 1 type 4b myocardial infarction ( MI ) one year .</brief_summary>
	<brief_title>Rapid Assessment Potential Ischaemic Heart Disease With CTCA</brief_title>
	<detailed_description>DESIGN : Open parallel group randomise control trial early compute tomography coronary angiography ( CTCA ) patient present suspected/confirmed acute coronary syndrome ( ACS ) Emergency Departments ( ED ) Medical Assessment Units . SETTING : 30 EDs , radiology , cardiology acute medical service tertiary/district general NHS hospital . TARGET POPULATION Inclusion Criteria : Patient ≥18 year symptoms mandate investigation suspect confirmed ACS least one : ECG abnormality e.g . ST segment depression &gt; 0.5 mm ; History ischaemic heart disease ( clinician assess patient confirms history base patient history available record ) ; Troponin elevation 99th centile normal reference range increase high sensitivity troponin meet European Society Cardiology criterion 'rule-in ' myocardial infarction ( NB troponin assay vary site site ; local laboratory reference standard use ) . Exclusion Criteria : 1.Signs , symptom , investigation support high-risk ACS : ST elevation MI ; ACS sign symptom acute heart failure circulatory shock ; Crescendo episodes typical anginal pain ; Marked dynamic ECG change e.g . ST depression &gt; 3 mm ; Clinical team schedule early invasive coronary angiography day trial eligibility assessment . 2 . Patient inability undergo CT : Severe renal failure ( serum creatinine &gt; 250 µmol/L estimate glomerular filtration rate &lt; 30 mL/min ) ; Contrast allergy ; Beta blocker intolerance ( alternative heart rate limit agent available/suitable ) allergy ; Inability breath hold ; Atrial fibrillation ( mean heart rate anticipate great 75 beat per minute beta blockade ) . 3 . Patient invasive coronary angiography CTCA within last 2 year previous investigation reveal obstructive coronary artery disease , patient either investigation within last 5 year result normal . 4.Previous recruitment trial ; 5.Known pregnancy currently breast feeding ; 6 . Inability consent ; 7.Further investigation ACS would patient 's interest , due limit life expectancy , quality life functional status ; 8.Prisoners HEALTH TECHNOLOGIES BEING ASSESSED : Early use ≥64-slice CTCA part routine assessment compare standard care . MEASUREMENT OF COSTS/OUTCOMES : Primary end-point one-year all-cause death recurrent type 1 MI . Secondary endpoint : 1 . Hospital stay , coronary care stay ; 2 . Proportion patient receive invasive coronary angiography index hospitalisation ; 3 . Proportion patient receive coronary revascularisation index hospitalisation ; 4 . Proportion patient receive subsequent unplanned coronary revascularisation index hospitalisation ; 5 . Proportion patient receive invasive coronary angiography despite significant lesion CTCA ; 6 . Proportion patient prescribe ACS therapy and/or discharge secondary prevention treatment index hospitalisation ; 7 . Rehospitalisation/presentation chest pain within 12 month ; 8 . Patient symptom quality life 12 month ; 9 . NHS resource utilisation ; 10 . Patient satisfaction . Safety : 1 . Proportion patient allergy/anaphylaxis/acute kidney injury ; 2 . Proportion patient alternative diagnosis e.g . aortic dissection incidental potentially concern e.g . malignancy ; 3 . Total radiation exposure arm . Cost effectiveness : estimate term lifetime incremental cost per quality-adjusted life year ( QALY ) gain . SAMPLE SIZE : 2,500 patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA Patient ≥18 year symptoms mandate investigation suspect confirmed ACS least one : ECG abnormality e.g . ST segment depression &gt; 0.5 mm ; History ischaemic heart disease ( clinician assess patient confirms history base patient history available record ) ; Troponin elevation 99th centile normal reference range increase high sensitivity troponin meet European Society Cardiology criterion 'rulein ' myocardial infarction ( NB troponin assay vary site site ; local laboratory reference standard use ) . EXCLUSION CRITERIA Signs , symptom , investigation support highrisk ACS : ST elevation MI ; ACS sign symptom acute heart failure circulatory shock ; Crescendo episodes typical anginal pain ; Marked dynamic ECG change e.g . ST depression &gt; 3 mm Clinical team schedule early invasive coronary angiography day trial eligibility assessment . Patient inability undergo CT : Severe renal failure ( serum creatinine &gt; 250 µmol/L estimate glomerular filtration rate &lt; 30 mL/min ) ; Contrast allergy ; Beta blocker intolerance ( alternative heart rate limit agent available/suitable ) allergy ; Inability breath hold ; Atrial fibrillation ( mean heart rate anticipate great 75 beat per minute beta blockade ) . Patient invasive coronary angiography CTCA within last 2 year previous investigation reveal obstructive coronary artery disease , patient either investigation within last 5 year result normal . Previous recruitment trial ; Known pregnancy currently breast feeding ; Inability consent ; Further investigation ACS would patient 's interest , due limit life expectancy , quality life functional status ; Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Radiology</keyword>
	<keyword>Acute Medicine</keyword>
	<keyword>Emergency Medicine</keyword>
	<keyword>Cardiology</keyword>
</DOC>